Pharmaceutical - Pharmaceutical, Abilify Maintena

Filter

Popular Filters

Abilify Maintena shows superior efficacy to paliperidone palmitate

Abilify Maintena shows superior efficacy to paliperidone palmitate

04-11-2014

Danish CNS specialist Lundbeck and the US subsidiary of Japan’s Otsuka Pharmaceutical have released…

Abilify MaintenaLundbeckNeurologicalOtsuka Pharmaceuticalpaliperidone palmitatePharmaceuticalResearch

US FDA accepts for review Otsuka and Lundbeck’s sNDA for Abilify Maintena

US FDA accepts for review Otsuka and Lundbeck’s sNDA for Abilify Maintena

30-04-2014

Danish CNS specialist Lundbeck and the US subsidiary of Japan’s Otsuka Pharmaceutical revealed that…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalRegulationUSA

Abilify Maintena cuts hospitalization rates for patients with schizophrenia vs oral antipsychotics

07-04-2014

Danish CNS drug specialist Lundbeck and partner Japanese drugmaker Otsuka Pharmaceutical today announced…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck and Otsuka update on European launch of Abilify Maintena

Lundbeck and Otsuka update on European launch of Abilify Maintena

17-03-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical’s European subsidiary…

Abilify MaintenaEuropeLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

New schizophrenia drug Abilify to lead the market by 2016

New schizophrenia drug Abilify to lead the market by 2016

29-12-2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia…

AbilifyAbilify MaintenaFinancialGlobalLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

21-11-2013

Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Roche/Chugai's bitopertin set to garner $1.5 billion sales in 2022

23-08-2013

Swiss drug major Roche (ROG: SIX) and its majority-owned Japanese affiliate Chugai's glycine transporter-1…

AbilifyAbilify MaintenabitopertinChugai PharmaceuticalEuropeGenericsJanssenLundbeckMarkets & MarketingNeurologicalNorth AmericaOtsukaPaliperidonePharmaceuticalRocheSeroquelZyprexa

Positive trial results for Otsuka and Lundbeck's Abilify Maintena in schizophrenia

22-05-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578)) and Denmark's Lundbeck (LUND: DC) today (May 22)…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Otsuka and Lundbeck expand current Abilify collaboration

07-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Denmark-based CNS specialist Lundbeck (LUND:…

AbilifyAbilify MaintenabrexpiprazoleEuropeLicensingLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Back to top